Literature DB >> 34971365

Utilization of induced pluripotent stem cells to model the molecular network regulating congenital heart disease.

McKay M S Mullen1, Joseph C Wu1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 34971365      PMCID： PMC8859623          DOI： 10.1093/cvr/cvab373

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   13.081


× No keyword cloud information.
  12 in total

1.  Congenital heart disease in the general population: changing prevalence and age distribution.

Authors:  Ariane J Marelli; Andrew S Mackie; Raluca Ionescu-Ittu; Elham Rahme; Louise Pilote
Journal:  Circulation       Date:  2007-01-08       Impact factor: 29.690

2.  A novel mutation of GATA4 in a familial atrial septal defect.

Authors:  Ying Chen; Jun Mao; Ying Sun; Qiang Zhang; Hong-Bo Cheng; Wen-Hua Yan; Kwong Wai Choy; Hong Li
Journal:  Clin Chim Acta       Date:  2010-07-24       Impact factor: 3.786

Review 3.  Human stem cells for modeling heart disease and for drug discovery.

Authors:  Elena Matsa; Paul W Burridge; Joseph C Wu
Journal:  Sci Transl Med       Date:  2014-06-04       Impact factor: 17.956

Review 4.  Will iPSC-cardiomyocytes revolutionize the discovery of drugs for heart disease?

Authors:  Arne An Bruyneel; Wesley L McKeithan; Dries Am Feyen; Mark Mercola
Journal:  Curr Opin Pharmacol       Date:  2018-08-03       Impact factor: 5.547

Review 5.  Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics.

Authors:  Mary Ella Pierpont; Craig T Basson; D Woodrow Benson; Bruce D Gelb; Therese M Giglia; Elizabeth Goldmuntz; Glenn McGee; Craig A Sable; Deepak Srivastava; Catherine L Webb
Journal:  Circulation       Date:  2007-05-22       Impact factor: 29.690

Review 6.  Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.

Authors:  Gary Gintant; Paul Burridge; Lior Gepstein; Sian Harding; Todd Herron; Charles Hong; José Jalife; Joseph C Wu
Journal:  Circ Res       Date:  2019-09-19       Impact factor: 17.367

7.  Patient-specific iPSC-derived cardiomyocytes reveal abnormal regulation of FGF16 in a familial atrial septal defect.

Authors:  Lingqun Ye; You Yu; Zhen-Ao Zhao; Dandan Zhao; Xuan Ni; Yong Wang; Xing Fang; Miao Yu; Yongming Wang; Jun-Ming Tang; Ying Chen; Zhenya Shen; Wei Lei; Shijun Hu
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 10.787

8.  FGF16 regulated by miR-520b enhances the cell proliferation of lung cancer.

Authors:  Wenfeng He; Xia Liu; Zhijie Luo; Longmei Li; Xisheng Fang
Journal:  Open Med (Wars)       Date:  2021-03-15

Review 9.  Race and Genetics in Congenital Heart Disease: Application of iPSCs, Omics, and Machine Learning Technologies.

Authors:  McKay Mullen; Angela Zhang; George K Lui; Anitra W Romfh; June-Wha Rhee; Joseph C Wu
Journal:  Front Cardiovasc Med       Date:  2021-02-17

10.  Socioeconomic Mediators of Racial and Ethnic Disparities in Congenital Heart Disease Outcomes: A Population-Based Study in California.

Authors:  Shabnam Peyvandi; Rebecca J Baer; Anita J Moon-Grady; Scott P Oltman; Christina D Chambers; Mary E Norton; Satish Rajagopal; Kelli K Ryckman; Laura L Jelliffe-Pawlowski; Martina A Steurer
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.